Literature DB >> 16505173

Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy.

Kalliopi Pilichou1, Andrea Nava, Cristina Basso, Giorgia Beffagna, Barbara Bauce, Alessandra Lorenzon, Gianfranco Frigo, Andrea Vettori, Marialuisa Valente, Jeffrey Towbin, Gaetano Thiene, Gian Antonio Danieli, Alessandra Rampazzo.   

Abstract

BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterized by progressive myocardial atrophy with fibrofatty replacement. The recent identification of causative mutations in plakoglobin, desmoplakin (DSP), and plakophilin-2 (PKP2) genes led to the hypothesis that ARVC is due to desmosomal defects. Therefore, desmoglein-2 (DSG2), the only desmoglein isoform expressed in cardiac myocytes, was screened in subjects with ARVC. METHODS AND
RESULTS: In a series of 80 unrelated ARVC probands, 26 carried a mutation in DSP (16%), PKP2 (14%), and transforming growth factor-beta3 (2.5%) genes; the remaining 54 were screened for DSG2 mutations by denaturing high-performance liquid chromatography and direct sequencing. Nine heterozygous DSG2 mutations (5 missense, 2 insertion-deletions, 1 nonsense, and 1 splice site mutation) were detected in 8 probands (10%). All probands fulfilled task force criteria for ARVC. An endomyocardial biopsy was obtained in 5, showing extensive loss of myocytes with fibrofatty tissue replacement. In 3 patients, electron microscopy investigation was performed, showing intercalated disc paleness, decreased desmosome number, and intercellular gap widening.
CONCLUSIONS: This is the first investigation demonstrating DSG2 gene mutations in a significant number of ARVC-unrelated probands. Cardiac phenotype is characterized clinically by typical ARVC features with frequent left ventricular involvement and morphologically by fibrofatty myocardial replacement and desmosomal remodeling. The presence of mutations in desmosomal encoding genes in 40% of cases confirms that many forms of ARVC are due to alterations in the desmosome complex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505173     DOI: 10.1161/CIRCULATIONAHA.105.583674

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  168 in total

1.  Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.

Authors:  Anna R Hemnes; Aaron W Trammell; Stephen L Archer; Stuart Rich; Chang Yu; Hui Nian; Niki Penner; Mitchell Funke; Lisa Wheeler; Ivan M Robbins; Eric D Austin; John H Newman; James West
Journal:  Circulation       Date:  2014-10-31       Impact factor: 29.690

2.  Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise.

Authors:  Jamie D Kapplinger; Andrew P Landstrom; Benjamin A Salisbury; Thomas E Callis; Guido D Pollevick; David J Tester; Moniek G P J Cox; Zahir Bhuiyan; Hennie Bikker; Ans C P Wiesfeld; Richard N W Hauer; J Peter van Tintelen; Jan D H Jongbloed; Hugh Calkins; Daniel P Judge; Arthur A M Wilde; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2011-06-07       Impact factor: 24.094

Review 3.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

4.  Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria.

Authors:  Frank I Marcus; William J McKenna; Duane Sherrill; Cristina Basso; Barbara Bauce; David A Bluemke; Hugh Calkins; Domenico Corrado; Moniek G P J Cox; James P Daubert; Guy Fontaine; Kathleen Gear; Richard Hauer; Andrea Nava; Michael H Picard; Nikos Protonotarios; Jeffrey E Saffitz; Danita M Yoerger Sanborn; Jonathan S Steinberg; Harikrishna Tandri; Gaetano Thiene; Jeffrey A Towbin; Adalena Tsatsopoulou; Thomas Wichter; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-19       Impact factor: 29.690

5.  Loss of mXinalpha, an intercalated disk protein, results in cardiac hypertrophy and cardiomyopathy with conduction defects.

Authors:  Elisabeth A Gustafson-Wagner; Haley W Sinn; Yen-Lin Chen; Da-Zhi Wang; Rebecca S Reiter; Jenny L-C Lin; Baoli Yang; Roger A Williamson; Ju Chen; Cheng-I Lin; Jim J-C Lin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-08-31       Impact factor: 4.733

6.  Molecular composition of the intercalated disc in a spontaneous canine animal model of arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Eva M Oxford; Melanie Everitt; Wanda Coombs; Philip R Fox; Marc Kraus; Anna R M Gelzer; Jeffrey Saffitz; Steven M Taffet; N Sydney Moïse; Mario Delmar
Journal:  Heart Rhythm       Date:  2007-06-08       Impact factor: 6.343

7.  Enhancement of Cutaneous Wound Healing by Dsg2 Augmentation of uPAR Secretion.

Authors:  Felicia Cooper; Andrew M Overmiller; Anthony Loder; Donna M Brennan-Crispi; Kathleen P McGuinn; Molly R Marous; Theresa A Freeman; Natalia A Riobo-Del Galdo; Linda D Siracusa; James K Wahl; Mỹ G Mahoney
Journal:  J Invest Dermatol       Date:  2018-05-09       Impact factor: 8.551

8.  Absence of a primary role for TTN missense variants in arrhythmogenic cardiomyopathy: From a clinical and pathological perspective.

Authors:  Kai Chen; Jiangping Song; Zhen Wang; Man Rao; Liang Chen; Shengshou Hu
Journal:  Clin Cardiol       Date:  2018-05-11       Impact factor: 2.882

9.  Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes.

Authors:  Andrew M Overmiller; Jennifer A Pierluissi; Peter J Wermuth; Sami Sauma; Ubaldo Martinez-Outschoorn; Madalina Tuluc; Adam Luginbuhl; Joseph Curry; Larry A Harshyne; James K Wahl; Andrew P South; Mỹ G Mahoney
Journal:  FASEB J       Date:  2017-04-24       Impact factor: 5.191

Review 10.  Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Mark M Awad; Hugh Calkins; Daniel P Judge
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.